Emeritus Professor Warren Tate FRSNZ CNZM is an academic and researcher at the University of Otago in Dunedin, New Zealand. He is a Fellow of the Royal Society of New Zealand, and internationally, a Fellow of the Alexander von Humboldt Foundation of Germany, and was an International Research Scholar of the Howard Hughes Medical Institute of the United States. Initially he was a discovery molecular biologist with a fundamental interest in how proteins are made in our cells, and how protein synthesis and the genetic code arose. He was a co-discoverer of a new rare mechanism of gene regulation, translational frameshifting and investigated its relevance for HIV-1. Professor Tate is involved in the development of a potential therapeutic agent for Alzheimer's disease from a natural neuroprotective brain protein, secreted amyloid precursor protein alpha. His most recent study investigated how this protein affects the transcriptome and proteome of human neurons differentiated from stems cells to understand its protective role and involvement in memory mechanisms. His most recent research programme has been on Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS) focussing on preclinical studies with New Zealand patients to understand its biological basis. He has found molecular signatures for the illness supporting its biological basis and is now studying whether the post-Covid fatigue syndrome has the same molecular signatures as found in ME/CFS.
Emeritus Professor Warren Tate FRSNZ CNZM is an academic and researcher at the University of Otago in Dunedin, New Zealand. He is a Fellow of the Royal Society of New Zealand, and internationally, a Fellow of the Alexander von Humboldt Foundation of Germany, and was an International Research Scholar of the Howard Hughes Medical Institute of the United States. Initially he was a discovery molecular biologist with a fundamental interest in how proteins are made in our cells, and how protein synthesis and the genetic code arose. He was a co-discoverer of a new rare mechanism of gene regulation, translational frameshifting and investigated its relevance for HIV-1. Professor Tate is involved in the development of a potential therapeutic agent for Alzheimer's disease from a natural neuroprotective brain protein, secreted amyloid precursor protein alpha. His most recent study investigated how this protein affects the transcriptome and proteome of human neurons differentiated from stems cells to understand its protective role and involvement in memory mechanisms. His most recent research programme has been on Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS) focussing on preclinical studies with New Zealand patients to understand its biological basis. He has found molecular signatures for the illness supporting its biological basis and is now studying whether the post-Covid fatigue syndrome has the same molecular signatures as found in ME/CFS.